ArticleBMC cardiovascular disorders2026
Prognostic value of RDW and its derivatives in ICU patients with hypertensive chronic kidney disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) complicated with hypertension constitutes a major global public health burden. Early identification of reliable prognostic biomarkers is essential to optimize clinical management and reduce mortality among these patients.
methodsA total of 6,731 intensive care unit (ICU) patients with hypertensive CKD were enrolled from the MIMIC-IV database. Three hematological markers were analyzed: red blood cell distribution width (RDW), hemoglobin to RDW ratio (HRR), and RDW to platelet ratio (RPR). Cox regression, Kaplan-Meier, and restricted cubic spline analyses were used to evaluate associations with prognosis. ROC curves, C-index, NRI, and IDI assessed predictive performance and incremental value, and decision curve analysis (DCA) evaluated clinical net benefit. Subgroup and sensitivity analyses were also performed.
resultsAmong 6,731 patients with hypertensive CKD, 2,505 (37.2%) died within one year. After multivariate adjustment, elevated RDW was associated with an increased risk of one-year all-cause mortality (HR = 1.19, 95% CI: 1.16-1.21, P < 0.001), while a higher HRR correlated with reduced mortality risk (HR = 0.89, 95% CI: 0.87-0.91, P < 0.001). The RPR showed a U-shaped correlation with one-year all-cause mortality. The areas under the ROCs for RDW, HRR and RPR were 0.668, 0.600 and 0.515, respectively. RDW and HRR can improve the predictive performance of conventional risk models, while the incremental value of RPR was heterogeneous and limited to specific scoring systems. DCA demonstrated that RDW, HRR, and RPR all provided favorable clinical net benefits across a wide range of high-risk thresholds, suggesting their potential clinical applicability. Subgroup analyses demonstrated significant interactions of RDW with CRRT use and CKD stage (P < 0.001), as well as a notable interaction between HRR and CRRT (P < 0.001). Sensitivity analysis verified the robustness of the present findings.
conclusionsRDW, HRR and RPR are associated with one-year mortality in ICU patients with hypertensive CKD. RDW exhibited modest predictive discrimination among the three markers and provides supplementary information for risk stratification when combined with established clinical risk scores. Prospective studies with external validation are warranted to confirm these findings and elucidate underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.